S F Roy1, F M Ghazawi2, M Le3, F Lagacé3,4, C F Roy4, E Rahme5, E Savin3, A Zubarev3, D Sasseville3, G Popradi6, I V Litvinov3. 1. Division of Pathology, University of Montreal, Montreal, QC. 2. Division of Dermatology, University of Ottawa, Ottawa, ON. 3. Division of Dermatology, McGill University, Montreal, QC. 4. Faculty of Medicine, McGill University, Montreal, QC. 5. Division of Clinical Epidemiology, McGill University, Montreal, QC. 6. Division of Hematology, McGill University, Montreal, QC.
Abstract
Background: Although the pathogenesis and epidemiology of endemic Burkitt lymphoma (bl) have been extensively studied, the epidemiologic landscape of sporadic and immunodeficiency-associated bl in North America remains poorly understood. Methods: We used 3 distinct population-based cancer registries to retrospectively study bl incidence and mortality in Canada. Data for patient sex; age at the time of diagnosis; and reporting province, city, and forward sortation area (fsa, the first three characters of a postal code) were analyzed. Results: During 1992-2010, 1420 patients with bl in Canada were identified (incidence rate: 2.40 cases per million patient-years), of which 71.1% were male patients. Mean age at diagnosis was 55.5 ± 20.8 years. A bimodal incidence by age distribution was seen in both sexes, with pediatric- and adult-onset peaks. An analysis based on fsas identified select communities with statistically higher rates of adult bl. Several of those fsas were located within the 3 major metropolitan areas (Montreal, Vancouver, Toronto) and within self-identified lgbtq communities. The fsas with a higher socioeconomic status score were associated with lower rates of bl. Conclusions: Current results highlight the geographic and historic pattern of bl in Canada. The human immunodeficiency virus remains an important risk factor for adult bl. 2020 Multimed Inc.
Background: Although the pathogenesis and epidemiology of endemic Burkitt lymphoma (bl) have been extensively studied, the epidemiologic landscape of sporadic and immunodeficiency-associated bl in North America remains poorly understood. Methods: We used 3 distinct population-based cancer registries to retrospectively study bl incidence and mortality in Canada. Data for patient sex; age at the time of diagnosis; and reporting province, city, and forward sortation area (fsa, the first three characters of a postal code) were analyzed. Results: During 1992-2010, 1420 patients with bl in Canada were identified (incidence rate: 2.40 cases per million patient-years), of which 71.1% were male patients. Mean age at diagnosis was 55.5 ± 20.8 years. A bimodal incidence by age distribution was seen in both sexes, with pediatric- and adult-onset peaks. An analysis based on fsas identified select communities with statistically higher rates of adult bl. Several of those fsas were located within the 3 major metropolitan areas (Montreal, Vancouver, Toronto) and within self-identified lgbtq communities. The fsas with a higher socioeconomic status score were associated with lower rates of bl. Conclusions: Current results highlight the geographic and historic pattern of bl in Canada. The human immunodeficiency virus remains an important risk factor for adult bl. 2020 Multimed Inc.
Entities:
Keywords:
Burkitt lymphoma, adult; Burkitt lymphoma, pediatric; HIV; epidemiology in Canada; human immunodeficiency virus; incidence in Canada; mortality in Canada
Authors: L Amar; M Le; F M Ghazawi; E Rahme; A Segal; E Netchiporouk; G Popradi; L Moreau; O Roshdy; D Sasseville; I V Litvinov Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Feras M Ghazawi; Janelle Cyr; Rami Darwich; Michelle Le; Elham Rahme; Linda Moreau; Elena Netchiporouk; Andrei Zubarev; Osama Roshdy; Steven J Glassman; Denis Sasseville; Ivan V Litvinov Journal: J Am Acad Dermatol Date: 2018-08-06 Impact factor: 11.527
Authors: Feras M Ghazawi; Rami Darwich; Michelle Le; Elham Rahme; Andrei Zubarev; Linda Moreau; Julia Valdemarin Burnier; Denis Sasseville; Miguel N Burnier; Ivan V Litvinov Journal: Br J Ophthalmol Date: 2019-02-28 Impact factor: 4.638
Authors: Feras M Ghazawi; Elena Netchiporouk; Elham Rahme; Matthew Tsang; Linda Moreau; Steven Glassman; Nathalie Provost; Martin Gilbert; Sara-Elizabeth Jean; Kevin Pehr; Denis Sasseville; Ivan V Litvinov Journal: Cancer Date: 2017-05-10 Impact factor: 6.860
Authors: Sam M Mbulaiteye; William F Anderson; Jacques Ferlay; Kishor Bhatia; Cindy Chang; Philip S Rosenberg; Susan S Devesa; Donald M Parkin Journal: Am J Hematol Date: 2012-04-10 Impact factor: 10.047
Authors: Matthew Tsang; Michelle Le; Feras M Ghazawi; Janelle Cyr; Akram Alakel; Elham Rahme; François Lagacé; Elena Netchiporouk; Linda Moreau; Andrei Zubarev; Osama Roshdy; Steven J Glassman; Denis Sasseville; Gizelle Popradi; Ivan V Litvinov Journal: Cancer Date: 2019-04-05 Impact factor: 6.860
Authors: Sam M Mbulaiteye; William F Anderson; Kishor Bhatia; Philip S Rosenberg; Martha S Linet; Susan S Devesa Journal: Int J Cancer Date: 2010-04-01 Impact factor: 7.396
Authors: Feras M Ghazawi; Michelle Le; François Lagacé; Janelle Cyr; Nebras Alghazawi; Andrei Zubarev; Simon F Roy; Elham Rahme; Elena Netchiporouk; Osama Roshdy; Steven J Glassman; Denis Sasseville; Ivan V Litvinov Journal: J Cutan Med Surg Date: 2019-05-27 Impact factor: 2.092
Authors: Santina Conte; Feras M Ghazawi; Michelle Le; Hacene Nedjar; Akram Alakel; François Lagacé; Ilya M Mukovozov; Janelle Cyr; Ahmed Mourad; Wilson H Miller; Joël Claveau; Thomas G Salopek; Elena Netchiporouk; Robert Gniadecki; Denis Sasseville; Elham Rahme; Ivan V Litvinov Journal: Front Med (Lausanne) Date: 2022-03-03
Authors: Dana N Muhealdeen; Alan Shwan; Rafil T Yaqo; Hemin A Hassan; Bryar O Muhammed; Rawa M Ali; Michael D Hughson Journal: Infect Agent Cancer Date: 2022-07-27 Impact factor: 3.698